Etalocib

DB12850InvestigationalSmall molecule

Etalocib has been used in trials studying the treatment of Pancreatic Cancer, Carcinoma, Non-Small-Cell Lung, and Unspecified Adult Solid Tumor, Protocol Specific.

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptor gamma and Leukotriene B4 receptor 1
Curator reviewed
Formula / weight: C₃₃H₃₃FO₆ · 544.619 g/mol (avg)
Code names: LY293111

Resolves to

Compound

UNIITHY6RIW44RCAS161172-51-6ChEMBLCHEMBL329123PubChem177941

Structure

InChIKeyYFIZRWPXUYFCSN-UHFFFAOYSA-NSMILESCCCC1=C(OCCCOC2=CC(O)=C(C=C2CC)C2=CC=C(F)C=C2)C=CC=C1OC1=CC=CC=C1C(O)=O

Targets

P37231PPARGQ15722LTB4R

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Etalocib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account